

Global Congress on Neurology

Sarah Smith

We are overwhelmed to announce” which is going to be held during “6th Global Congress on Neurology and Neurological disorders” on Nov 11-12, 2020 New York,USA.

NEUROLOGY GLOBALLY: Neurology is considered as the world’s fastest growing chronic condition. The Neurology is growing highly in each country. In 2013, Neurology caused 1.6 million deaths globally.

Neurology 2020 Conference invites all renowned scientists, dieticians, neurologists, primary health care specialists, surgeons, pharmaceutical industrial delegates, radiation therapists, general physicians, talented young scientists, and student communities across the globe to attend International Neurology 2020.


The major share in Neurology testing market share is held by companies such as Abbott Laboratories, AB Sciex, Agilent Technologies, Biomedical Technologies, Biomerieux SA, Bio Rad Laboratories, DiaSorin, Hoffmann-La Roche Ltd., LabCorp, and Quest Diagnostics.

Growing incidences of Neurology disorders such as hyperthyroidism and adrenal insufficiency is predicted to boost the demand for Neurology testing. Furthermore, growing healthcare awareness among individuals coupled with increasing government support is expected to increase the diagnosis at an early, thereby contributing to the growth of the Neurology testing market.

The players are actively involved in launching technologically advanced products and initiate collaborative developments to sustain themselves in the competition. For instance, LabCorp offers all-embracing solutions on clinical trials pertaining to Neurology and all other hormonal diseases.

The global Next Generation Neurology Therapy And Drug Delivery Market generated \$1.25 billion in 2017 and is estimated to reach \$9.67 billion by 2023, growing at a CAGR of 40.6% from 2018 to 2023. The report offers a detailed analysis of changing market trends, key investment pockets, major segments, geographical regions, and competitive scenario.

The CGM systems segment accounted for more than nine-tenths of the total revenue in 2017 and will maintain its dominance by 2023. This is due to various benefits including ease of usability and detection of levels of blood glucose. The report also explores inhalable insulin, oral insulin, and artificial pancreas.



Importance & Scope:

The Editors will concentrate on studies that involve wisely selected reports that provide a link between basic research and translation to neuroscience. The editors support the diffusion of distinctive solutions to challenging scientific and translational questions related with studies of Neurology and metabolically/genetically related disorders. Presumably, scientists in all disciplines related to Neurology and various scientists devoted to Glucose Metabolic Homeostasis and related subjects will engage as authors of JDRT articles. Most likely those studies would be focused on indicators of disease risk and mechanisms of glucose metabolic dysregulation related diseases.

Sarah Smith

Doctor, Department of neurology, NH hospital for Neurology, UK, E-mail: ssmith85@gmail.com